Sama provided critical feedback and comments on the Drugs and Cosmetics (Amendment) Bill, 2015. While acknowledging the positive aspects of the proposed amendments that were missing in the Drugs and Cosmetics Act earlier, Sama’s inputs focused primarily on sections dealing with clinical trials.
What’s New